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Filamentous actin (F-actin)This study demonstrated that exchange proteins directly activated by cAMP (Epac) and protein kinase A
(PKA) by 8-bromo (8-Br)-adenosine 3′,5′-cyclic monophosphate (cAMP) stimulated [14C]-α-methyl-D-
glucopyranoside (α-MG) uptake through increased sodium-glucose cotransporters (SGLTs) expression and
translocation to lipid rafts in renal proximal tubule cells (PTCs). In PTCs, SGLTs were colocalized with lipid
raft caveolin-1 (cav-1), disrupted by methyl-β-cyclodextrin (MβCD). Selective activators of Epac or PKA,
8-Br-cAMP, and forskolin stimulated expressions of SGLTs and α-MG uptake in PTCs. In addition, 8-Br-
cAMP-induced PKA and Epac activation increased phosphorylation of extracellular signal-regulated kinase
(ERK), p38 mitogen-activated protein kinase (MAPK), and nuclear factor kappa B (NF-κB), which were
involved in expressions of SGLTs. Furthermore, 8-Br-cAMP stimulated SGLTs translocation to lipid rafts via
ﬁlamentous actin (F-actin) organization, which was blocked by cytochalasin D. In addition, cav-1 and
SGLTs stimulated by 8-Br-cAMP were detected in lipid rafts, which were blocked by cytochalasin D. Further-
more, 8-Br-cAMP-induced SGLTs translocation and α-MG uptake were attenuated by inhibition of cav-1
activation with cav-1 small interfering RNA (siRNA) and inhibition of F-actin organization with TRIO and
F-actin binding protein (TRIOBP). In conclusion, 8-Br-cAMP stimulated α-MG uptake via Epac and
PKA-dependent SGLTs expression and trafﬁcking through cav-1 and F-actin in PTCs.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
The glucose reabsorption system in the kidney is mediated by so-
dium/glucose cotransporters (SGLTs) located in the renal proximal
tubule cells (PTCs), which are regulated by various signaling mole-
cules. A large body of experimental observations demonstrated that
in normal kidneys, adenosine 3′,5′-cyclic monophosphate (cAMP) is
elevated by agonists such as arginine vasopressin (AVP), prostaglan-
din E2 (PGE2), secretin, and vasoactive intestinal polypeptide (VIP)
[1]. In addition, cAMP is generated in response to imbalance between
energy demand and supply (e.g. diabetes, hypoxia, increased tubular
Na+/Cl− transport) to affect renal vascular and tubular functions [2].
Furthermore, exogenous cAMP converting to adenosine in response
to hypoglycemia might increase the efﬁciency of glucose transport,
an adaptive mechanism to combat hypoglycemia [3]. However, the
cellular mechanism by which cAMP inﬂuences the SGLT function of
the renal proximal tubules has not yet been elucidated, but we postu-
late that intracellular cAMP could act on the PTCs by binding to cAMP-
dependent proteins, such as protein kinase A (PKA) and exchange82 2 885 2732.
rights reserved.protein directly activated by cAMP (Epac). In many experiments, per-
meating analogs of cAMP, such as 8-bromoadenosine (8-Br)-cAMP,
have been used to mimic the effects of hormone stimulation on target
tissues since cAMP is known not to penetrate cells to a signiﬁcant ex-
tent. In addition, SGLT1 localization is associated with detergent-
resistant membrane microdomains [4] and cytoskeletal elements
are known to participate in the constitution of lipid microdomains
[5,6]. Although there has been controversy about lipid raft size, stabil-
ity, and proper deﬁnition, there is consensus view that lipid rafts have
a large number of cellular functions ranging from protein and lipid
sorting to regulation of cell signaling of membrane proteins [7–10].
Indeed, vesicle trafﬁcking of SGLTs (including exocytic insertion,
endocytic retrieval, and recycling to and from the plasma membrane)
is likely to play a major role in SGLT regulation. Therefore, further
studies will be necessary to determine the role of cAMP in the regula-
tion of SGLT expression and membrane trafﬁcking and the speciﬁc in-
tracellular messengers that mediate this process. Despite its
importance, the regulatory mechanism of SGLTs expression and/or
translocation by cAMP has not been thoroughly studied in PTCs.
In epithelial cells, cAMP stimulates protein trafﬁcking by activat-
ing two ubiquitously expressed intracellular cAMP receptors, the clas-
sic PKA and/or the recently discovered Epac [11–13]. Recent reports
demonstrated that the cAMP/Epac signaling pathway inﬂuences cel-
lular ion channels or transporter activity in regulating a speciﬁc
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[11,15–19]. However, the relation between Epac and PKA for SGLT
regulation by cAMP and its related downstream mechanisms are not
completely understood in PTCs. Our previous studies using a cell
model of primary cultured renal PTCs with [14C]-α-methyl-D-gluco-
pyranoside (α-MG) uptake indicated that these cells maintain the ac-
tivity of their transport system in culture [20,21]. Thus, outcomes
from membrane transport studies using these PTCs could be com-
pared directly to the original renal tissue. In addition, PTCs in hor-
monally deﬁned, serum-free culture conditions provide a valuable in
vitro model for examining the effect of cAMP on renal SGLTs. Hence,
we determined the mechanism which 8-Br-cAMP regulates the ex-
pression and localization of SGLTs through both Epac and PKA depen-
dent pathways in renal PTCs.
2. Materials and methods
2.1. Animals and materials
New Zealand White male rabbits (1.5–2.0 kg) were purchased
from Dae Han Experimental Animal (Chungju, Korea). All animal
management procedures followed the standard operating protocols
of Seoul National University. The Institutional Review Board at Chon-
nam National University approved the research proposal and the rel-
evant experimental procedures, including those for animal care. In
addition, authors are Doctors of Veterinary Medicine with licenses
granted from the Ministry of Agriculture and Forestry of the Republic
of Korea. Class IV collagenase, 8-Br-cAMP, forskolin, protein kinase in-
hibitor (PKI), PD98059, SB203580, cytochalasin D, methyl-β-
cyclodextrin (MβCD), ﬂuorescein isothiocyanate (FITC)-conjugated
anti-rabbit IgG, FITC-conjugated anti-mouse IgM, and monoclonal
anti-β-actin were obtained from Sigma-Aldrich (St. Louis, MO, USA).
Soybean trypsin inhibitor and Dulbecco's Modiﬁed Eagle's Medium
(DMEM)/F-12 medium were purchased from Gibco BRL (Grand Is-
land, NY, USA). 8-(4-chlorophenylthio)-2′-O-methyladenosine-3′,5′-
cyclic monophosphate (8-CPT-2′-O-Me-cAMP) and N6-phenyladeno-
sine-3′,5′-cyclic monophosphate (6-Phe-cAMP) were purchased from
Biolog Life Science Institute (Bremen, Germany). SN50 was acquired
from Calbiochem (La Jolla, CA, USA). [14C]-α-MG was purchased
from DuPont/NEN (Boston, MA, USA). Goat anti-rabbit IgG, goat
anti-mouse IgG, normal rabbit IgG, PKA subunit α, SGLT1, SGLT2,
Epac, Ras-proximate-1 (Rap1), phospho-extracellular signal-
regulated kinase (ERK), phospho-p38, phospho-nuclear factor kappa
B (NF-κB), caveolin-1 (cav-1), zonula occludens-1 (ZO-1), and pan
cadherin were acquired from Santa Cruz Biotechnology (Santa Cruz,
CA, USA). Filamentous actin (F-actin) and β cop antibodies were
obtained from Abcam (Cambridge, MA, USA). Liquiscint was obtained
from National Diagnostics (Parsippany, NY, USA). All other reagents
used were of the highest purity commercially available.
2.2. Cell preparation and culture conditions
Primary rabbit renal PTC cultures were prepared as previously
described [22]. The PTCs were grown in DMEM/F-12 medium sup-
plemented with 15 mM HEPES (4-[2-hydroxyethyl]-1-piperazi-
neethanesulfonic acid) and 20 mM sodium bicarbonate (pH 7.4).
Three other growth supplements (5 μg/ml insulin, 5 μg/ml transfer-
rin, and 5×10−8 M hydrocortisone) were added immediately before
using the medium. Rabbit kidneys were perfused through the renal
artery, ﬁrst with phosphate buffered saline (PBS), and then with me-
dium containing 0.5% iron oxide. Renal cortical slices were prepared
and homogenized. The homogenate was poured sequentially
through 253-μm and 83-μm mesh ﬁlters. Tubules and glomeruli
retained by the 83-μm ﬁlter were transferred to sterile medium.
The glomeruli (which contained the iron oxide) were removed
using a magnetic stir bar. The remaining proximal tubules wereincubated brieﬂy in medium containing 0.125 mg/ml collagenase
and 0.025% soybean trypsin inhibitor, then washed by centrifuga-
tion, resuspended in medium containing the three supplements,
and transferred to tissue culture dishes. The medium was changed
one day after plating and every two days thereafter. The primary
cultured rabbit kidney PTCs were maintained at 37 °C in a 5% CO2
humidiﬁed environment in serum-free basal medium modiﬁed
with the three growth supplements.2.3. α-MG uptake studies
Analysis of α-MG uptake was carried out as described previously
[23]. Brieﬂy, the culture medium was removed by aspiration and
the monolayers gently washed twice with uptake buffer (136 mM
NaCl, 5.4 mM KCl, 0.41 mM MgSO4, 1.3 mM CaCl2, 0.44 mM
Na2HPO4, 0.44 mM KH2PO4, 5 mM HEPES, 2 mM glutamine, and
0.5 μg/ml BSA, pH 7.4). After washing, the monolayers were incubat-
ed for 30 min at 37 °C in uptake buffer containing 0.5 mM α-MG and
14C-α-MG (0.5 μCi/ml). At the end of the incubation period, the
monolayers were again washed three times with ice-cold uptake
buffer, and the cells were dissolved in 1 ml 0.1% sodium dodecyl sul-
fate (SDS). To measure intracellular incorporation of 14C-α-MG,
900 μl of each sample was removed and counted in a LS 6500 liquid
scintillation counter (Beckman Coulter, Fullerton, CA, USA). The re-
mainder of each sample was used to measure total protein levels
using the Bradford method [24]. The radioactive counts in each sam-
ple were subtracted count (cpm) of blank cocktail solution and nor-
malized to protein levels. And then, the normalized cpm were
corrected for zero-time uptake per mg of protein. All uptake measure-
ments were conducted in triplicate.2.4. Detergent-free puriﬁcation of cav-rich membrane fraction
Cav-enriched membrane fractions were prepared as described
previously [25]. Cells were washed twice with ice-cold PBS and
scraped into 2 ml of 500 mM sodium carbonate (pH 11.0), transferred
to a plastic tube, and homogenized with a Branson Sonicator 250 in
three 20 s bursts (Branson Ultrasonic, Danbury, CT, USA). The homog-
enate was then adjusted to 45% sucrose by the addition of 2 ml of 90%
sucrose prepared in MES-buffered solution (MBS: 25 mM MES [pH
6.5], 0.15 M NaCl) and placed at the bottom of an ultracentrifuge
tube. A 5–35% discontinuous sucrose gradient was formed (4 ml 5%
sucrose, 4 ml 35% sucrose, both in MBS containing 250 mM sodium
carbonate) and the tubes were centrifuged at 40,000 rpm for 20 h in
an SW 41 rotor (Beckman Instruments, Palo Alto, CA, USA). Twelve
fractions were from twelve 1 ml of four sucrose gradients. Each frac-
tion was collected and analyzed by SDS-polyacrylamide gel electro-
phoresis (PAGE).2.5. Immunoﬂuorescence staining with SGLTs, ZO-1, F-actin, or cav-1
Cells were ﬁxed in 4% paraformaldehyde for 10 min, permeabi-
lized in 0.1% Triton X-100 for 5 min, treated with a 1:50 dilution of
antibody against SGLT1, SGLT2, ZO-1, or cav-1 and incubated for
30 min with a 1:50 dilution of FITC-conjugated secondary antibody
raised in rabbit against goat IgG and goat against rabbit IgG, or anti-
mouse Alexa Fluor 588-conjugated secondary antibody (Invitrogen,
Carlsbad, CA, USA), respectively. Cells were also incubated for
30 min with Alexa Fluor 488-conjugated phalloidin (Invitrogen,
Carlsbad, CA, USA). Propidium iodide (Invitrogen, Carlsbad, CA,
USA) was added for DNA content. Fluorescent images were visualized
with a FluoView 300 ﬂuorescence microscope (Olympus, Tokyo,
Japan).
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Cells were grown in dishes until they reached 75% conﬂuence, at
which point they were transfected for 24 h with siRNA constructs tar-
geting Epac, Rap1, and cav-1 (ONTARGETplus SMARTpool; 100 nmol/
L, Dharmacon, Lafayette, CO, USA), TRIO and F-actin binding protein
(TRIOBP) (100 nmol/L, Bioneer, Daejeon, Republic of Korea), and a
non-targeting siRNA (negative control; 100 nmol/L, Dharmacon)
using Hyperfectamine (QIAGEN, Valencia, CA, USA), according to the
manufacturer's instructions.2.7. Immunoprecipitation
Cells were lysed with buffer (1% Triton X-100 in 50 mM Tris–HCl
[pH 7.4] containing 150 mM NaCl, 5 mM EDTA, 2 mM Na3VO4,
2.5 mM Na4PO7, 100 mM NaF, 200 nM microcystin-lysine-arginine,
and protease inhibitors). Cell lysates (300 μg) were mixed with
10 μg of cav-1 antibody. Samples were incubated for 4 h, mixed
with Protein A/G PLUS-agarose immunoprecipitation reagent (Pierce,
Rockford, IL, USA) and incubated for an additional 12 h. The beads
were washed four times, and the bound proteins were released
from the beads by boiling in SDS-PAGE sample buffer for 5 min. Sam-
ples were analyzed by Western blotting with cav-1, SGLT1, or SGLT2
antibodies.2.8. Preparation of cytosolic and membrane fraction
Once conﬂuent cultures were treated according to the indicated
conditions, the media was removed and the cells were washed
twice with ice-cold PBS, scraped, harvested by microcentrifugation,
and resuspended in Buffer A (137 mM NaCl, 8.1 mM Na2HPO4,
2.7 mM KCl, 1.5 mM KH2PO4, 2.5 mM EDTA, 1 mM dithiothreitol,
0.1 mM phenylmethanesulfonyl ﬂuoride, 10 μg/ml leupeptin [pH
7.5]). Resuspended cells were then lysed with a Branson Sonicator
250 in three 20 s bursts on ice. To prepare the cytosolic and particu-
late fractions, the lysates were centrifuged at 1,000 ×g for 10 min at
4 °C, after which the supernatants were centrifuged at 100,000 ×g
for 1 h at 4 °C. The particulate fraction, which contained the mem-
branes, was washed twice, resuspended in Buffer A containing 1%
(v/v) Triton X-100, and soniﬁcated. To conﬁrm the separation of cyto-
solic and membrane fraction, each fraction protein was blotted with
antibody against pan cadherin as a plasma membrane fraction mark-
er. Protein levels in each fraction were quantiﬁed using the Bradford
procedure [24].2.9. Western blot analysis
Cell homogenates (30 μg protein) were separated by 10% SDS-
PAGE and transferred to polyvinylidene ﬂuoride membranes. The
blots were washed with water, blocked for 1 h with 5% skim
milk powder in Tris-buffered saline Tween (TBST) (10 mM Tris–
HCl [pH 7.6], 150 mM NaCl, 0.05% Tween-20), and incubated
with primary polyclonal antibodies at the dilutions recommended
by the suppliers. Speciﬁcity of SGLT1 and SGLT2 antibodies was
conﬁrmed using control peptides. Due to its low molecular weight
(b3 kDa), the control peptide was not suitable for Western analy-
sis, and was therefore used for enzyme-linked immunosorbent
assay (ELISA) or antibody blocking to conﬁrm antibody speciﬁcity.
The membrane was washed and the primary antibodies were
detected using goat anti-rabbit-IgG conjugated to horseradish per-
oxidase. Immunoreactive bands were visualized using an enhanced
chemiluminescence procedure (Amersham Pharmacia Biotech,
Buckinghamshire, UK).2.10. Real-time polymerase chain reaction
Total RNA was extracted from cells treated with each designated
agent using STAT-60, a monophasic solution of phenol and guani-
dine isothiocyanate (Tel-Test, Friendswood, TX, USA). Real-time
quantiﬁcation of the RNA targets was performed using a Rotor-
Gene 6500 real-time thermal cycling system (Corbett Research,
NSW, Australia) and QuantiTect SYBR Green Real-time PCR Kits
(QIAGEN). The reaction mixture (20 μl) contained 200 ng of total
RNA, 0.5 μM of each primer, the appropriate amounts of enzymes,
and ﬂuorescent dyes, as recommended by the supplier. A Rotor-
Gene 6500 cycler was programmed as follows: 30 min at 50 °C
for reverse transcription; 15 min at 95 °C for DNA polymerase acti-
vation; 15 s at 95 °C for denature; 40 cycles of 15 s at 94 °C, 30 s
at 55 °C, and 30 s at 72 °C. The data was collected during the ex-
tension step (30 s at 72 °C). The PCR reaction was followed by
melting curve analysis, which can distinguish between speciﬁc
PCR products and the non-speciﬁc PCR products resulting from
primer-dimer formation to conﬁrm the speciﬁcity and identity of
the Real-time PCR products. Primers were 5′-TCCTCACCCTTTGG-
TACTGG-3′ (forward) and 5′- ACAGGATACGGCTCACCATC-3′
(reverse) for SGLT1 [26], and 5′- AGGATCCATCTGTTGGCA-3′
(forward) and 5′-ACGGGGCACAAAGAGT-3′ (reverse) for SGLT2
[27]. The ampliﬁcation cycles were followed by a high resolution
melting cycle from 65 °C to 99 °C at a rate of 0.1 °C/2 s, and the
resulting data was analyzed using the software provided by the
manufacturer. When the melting temperature (Tm) is reached,
double stranded DNA is denatured and the SYBR is released
which cause a dramatic decrease in ﬂuorescence intensity. The
rate of this change was determined by plotting the derivative of
the ﬂuorescence relative to the temperature (dF/dT) vs.
temperature by the data analysis software of the Real-time PCR in-
strument. The temperature at which a peak occurs on the plot cor-
responds to the Tm of the DNA duplex. β-Actin as an endogenous
control was used for normalization and a control group was used
as a deﬁned calibrator.
2.11. Statistical analysis
Results are expressed as mean±standard error (SE). The differ-
ence between the two mean values was analyzed by ANOVA.
Pb0.05 was considered signiﬁcant.
3. Results
3.1. Effect of 8-Br-cAMP on SGLT expression and localization to lipid rafts
We ﬁrst examined where SGLTs are located and whether cav-1
interacts with SGLTs in PTCs. To assess whether SGLTs and cav-1
colocalized in lipid rafts, cell fractions were prepared by detergent
free puriﬁcation using discontinuous sucrose density gradient cen-
trifugation. The plasma membrane lipid raft fraction was found to
reside mainly in the light buoyant membranes (Fig. 1A, fractions
5 and 6). Western blot analysis for SGLTs and cav-1 demonstrated
localization of SGLTs in the lipid rafts fraction. On the other hand,
β Cop as a marker of Golgi was observed in the cytosol (fractions
9–12). In order to examine the effect of cAMP on localization of
SGLTs, we conducted immunoﬂuorescence staining with antibodies
against SGLTs and tight junction protein, ZO-1. As shown in
Fig. 1B, 8-Br-cAMP increased the expression of SGLT1 as well as
SGLT2 and SGLTs were localized in apical membrane. We also con-
ducted immunoprecipitation experiments using cav-1 antibody or
normal IgG as a negative control to detect the complex of SGLTs.
8-Br-cAMP (100 μM), a membrane permeable cAMP analog, in-
creased SGLT expression binding to cav-1 (Fig. 1C). In addition,
disruption of membrane lipid rafts with MβCD (5 mM)
Fig. 1. Effect of cAMP on SGLT expression and localization to lipid rafts. A: Proximal tubule cells (PTCs) were subjected to sucrose density gradient fractionation. Each fraction was
assessed by Western blot analysis. B: Immunoﬂuorescence laser confocal images for SGLTs and ZO-1. The x-y optical sections are shown in the upper large panels, and an x–z, y–z
vertical scanning image of each upper panel is shown in the lower small panel. Green and red signals indicate the SGLT and ZO-1, respectively. The scale bar indicates 20 μm. C: After
cells were treated with 8-Br-cAMP, immunoprecipitation of anti-cav-1 or normal IgG was analyzed by Western blotting with antibodies that recognize SGLT1 or SGLT2. Each ex-
ample shown is representative of three experiments. D: Cells were pretreated with MβCD (5 mM) for 30 min prior to 8-Br-cAMP treatment. Membrane protein was extracted
and blotted with antibodies against SGLT1, SGLT2, or β-actin. The lower panels denote the means±standard error (SE) of three experiments for each condition determined
from densitometry relative to β-actin. *Pb0.05 vs. control, **Pb0.05 vs. cAMP alone.
974 Y.J. Lee et al. / Biochimica et Biophysica Acta 1823 (2012) 971–982signiﬁcantly attenuated 8-Br-cAMP-induced SGLT expression in
membrane fractions (Fig. 1D). These data showed that cAMP stim-
ulated SGLT expression and localization in lipid rafts of PTC plasma
membranes.
3.2. Relationship between Epac and PKA in SGLT and cav-1 expression
To examine the effect of 8-Br-cAMP-induced signaling molecules
on SGLT expression, we treated Epac activator (8-CPT-2′-O-Me-cAMP, 50 μM), PKA activator (6-Phe-cAMP, 50 μM), 8-Br-cAMP
(100 μM), and forskolin (1 μM) for 24 h. 8-CPT-2′-O-Me-cAMP in-
duced in expression of Epac and Rap1, but did not affect on PKA cat-
alytic subunit α (PKAα) expression. In contrast, 6-Phe-cAMP
increased PKAα expression, but did not elicit any changes in Epac
and Rap1 expression. Both 8-Br-cAMP and forskolin increased expres-
sions of Epac, Rap1, and PKAα (Fig. 2A). In addition, these treatments
induced localization of SGLT1 and SGLT2 in membrane fraction
(Fig. 2B). Consistent with this result, Epac- or Rap1-speciﬁc siRNA
Fig. 2. Effect of cAMP-induced Epac and PKA on SGLT expression. PTCs were treated with Epac activator (8-CPT-2′-O-Me-cAMP, 50 μM), PKA activator (6-Phe-cAMP, 50 μM), 8-Br-
cAMP (100 μM), and forskolin (1 μM) for 24 h. A: Total or plasma membrane protein was extracted and blotted with antibodies against Epac, PKAα (total), Rap1 (plasma
membrane), or β-actin. B: Membrane protein was extracted and blotted with antibodies against SGLT1 or SGLT2. Each example shown is representative of three independent
experiments. The lower panels denote the means±SE of three experiments for each condition determined from densitometry relative to β-actin. *Pb0.05 vs. control. C–D: Cells
were transfected with either a SMARTpool of Epac siRNAs, Rap1 siRNAs (100 nmol/L), or a non-targeting control siRNA (100 nmol/L) using Hyperfectamine prior to 8-Br-cAMP
treatment for 24 h (C). Cells were pretreated with PKI (1 μM) for 30 min prior to 8-Br-cAMP treatment for 24 h (D). Protein expression of SGLT1, SGLT2, Cav-1, Epac, or Rap1
was monitored by Western blotting. Each example shown is representative of three independent experiments. The lower panels denote the means±SE of three experiments
for each condition determined from densitometry relative to β-actin. *Pb0.05 vs. control, **Pb0.05 vs. cAMP alone.
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ment in expressions of SGLTs and cav-1 in membrane fractions
(Fig. 2C and D). In immunoﬂuorescence staining, Epac activator,
PKA activator, 8-Br-cAMP, and forskolin increased the expressions of
SGLT1 and SGLT2 (Fig. 3A). In addition to SGLTs expression, SGLTs ac-
tivity was measured byα-MG uptake. As we expected, Epac/Rap1 and
PKA activation signiﬁcantly increased α-MG uptake (Fig. 3B), which
was blocked by each inhibitor (Fig. 3C).
In experiments to determine the involvement of MAPKs and NF-
κB as downstream signaling pathways of cAMP-induced Epac and
PKA activation in SGLTs protein expression, 8-Br-cAMP increased
SGLTs mRNA and protein expression as well as cav-1 expression in
total fraction which was completely abolished by 30 min pretreat-
ment with PD98059 (ERK MAPK inhibitor, 10 μM), SB203580 (p38
MAPK inhibitor, 1 μM), or SN50 (NF-κB nuclear translocation inhibi-
tor, 500 ng/ml) (Fig. 4A and B). These results were conﬁrmed by the
fact that 8-Br-cAMP-induced α-MG uptake was inhibited by
PD98059, SB203580, or SN50 treatment (Fig. 4C). In addition, 8-Br-
cAMP-induced ERK, p38 MAPK, and NF-κB phosphorylations which
were blocked by treatment with Epac or Rap1 siRNA and PKI
(Fig. 4D and E).Fig. 3. Effect of cAMP-induced Epac and PKA on α-MG uptake. PTCs were treated with Epac a
immunoﬂuorescent stained samples, cells were ﬁxed and stained with a primary antibody a
C: Cells were transfected with a SMARTpool of Epac siRNAs, Rap1 siRNAs, or a non-targetin
cAMP treatment for 24 h, after which α-MG uptake was measured. Values are reported as th
trol, **Pb0.05 vs. cAMP alone.3.3. Interaction of F-actin and cav-1 in 8-Br-cAMP-induced SGLT translo-
cation to lipid rafts
To examine how SGLTs translocated into lipid rafts of cell mem-
brane, 8-Br-cAMP-induced expression of F-actin was determined. In
immunoﬂuorescence staining, 8-Br-cAMP signiﬁcantly increased F-
actin expression (Fig. 5A). 8-Br-cAMP-induced F-actin expression in
total fraction was inhibited by Epac- and Rap1-speciﬁc siRNAs or
PKI (Fig. 5B and C). To further analyze the effect of F-actin on SGLT lo-
calization in lipid raft fractions, we conducted western blotting to ex-
amine SGLTs expression in total, cytosol, and membrane fractions
after treatment with cytochalasin D (inhibitor of actin polymeriza-
tion, 10 μM). 8-Br-cAMP increased the expression levels of SGLTs in
both cytosol and membrane fraction. Cytochalasin D did not change
8-Br-cAMP-elicited SGLT expression in total and cytosol fractions
but markedly inhibited the membrane distribution of SGLT1 and
SGLT2 by 8-Br-cAMP (Fig. 5D). Moreover, PTCs were treated with cy-
tochalasin D or cav-1 siRNA prior to 8-Br-cAMP. As shown in Fig. 6A,
double labeling immunoﬂuorescence staining revealed that SGLTs
and cav-1 colocalized at the plasma membrane after treatment with
8-Br-cAMP. However, when PTCs were pretreated with cytochalasinctivator, PKA activator, 8-Br-cAMP, and forskolin for 24 h. A: For confocal microscopy of
gainst SGLT1 and SGLT2. The scale bar indicates 50 μm. B: α-MG uptake was measured.
g control siRNA using Hyperfectamine or pretreated with PKI for 30 min prior to 8-Br-
e mean ± SE of three independent experiments from triplicate dishes. *Pb0.05 vs. con-
Fig. 4. Involvement of MAPKs and NF-κB in cAMP-induced SGLT protein expression and α-MG uptake. A–C: PTCs were pretreated with PD98059 (ERK MAPKs inhibitor, 10−5 M),
SB203580 (p38 MAPK inhibitor, 10−6 M), or SN50 (NF-κB nuclear translocation inhibitor, 500 ng/ml) for 30 min prior to 8-Br-cAMP treatment for 24 h. SGLT1 and SGLT2 mRNA
expression levels were analyzed by Real-Time PCR (A). Protein expressions of SGLT1, SGLT2, and cav-1 were monitored by Western blotting (B). Each example shown is represen-
tative of three independent experiments. The α-MG uptake was also measured (C). The values are reported as the mean±SE of four independent experiments from triplicate
dishes. *Pb0.05 vs. control, **Pb0.05 vs. cAMP alone. D, E: Cells were transfected with a SMARTpool of Epac siRNAs, Rap1 siRNAs, or a non-targeting control siRNA using hyperfec-
tamine, or pretreated with PKI for 30 min prior to 8-Br-cAMP treatment for 24 h. Activations of ERK, p38 MAPK, and NF-κB were monitored by Western blotting. Each example
shown is representative of three independent experiments. The lower panel (B, D, and E) denotes the means±SE of three experiments for each condition determined from den-
sitometry relative to β-actin or total form of each protein. *Pb0.05 vs. control, **Pb0.05 vs. cAMP alone.
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the perinuclear region, showing that translocation of SGLT2 and cav-1
into membranes was blocked. In addition, knockdown of cav-1protein expression with siRNA down regulated the SGLT membrane
localization. Moreover, we noticed that 8-Br-cAMP-induced interac-
tion of cav-1 and SGLTs in membrane fractions and using
Fig. 5. Involvement of F-actin in cAMP-induced SGLT translocation to lipid rafts. A: After PTCs were treated with 8-Br-cAMP, for confocal microscopy of immunoﬂuorescent stained
samples, cells were ﬁxed and stained with antibodies against F-actin, and propidium iodide (10 μg/ml) was added. The scale bar indicates 50 μm. B, C: Cells were transfected with a
SMARTpool of Epac siRNAs, Rap1 siRNAs, or a non-targeting control siRNA using Hyperfectamine or pretreated with PKI for 30 min prior to 8-Br-cAMP treatment for 24 h. F-actin
was monitored by Western blotting. D: Cells were pretreated with cytochalasin D prior to 8-Br-cAMP treatment. Total protein or cytosol/membrane protein was extracted and blot-
ted with antibodies against SGLT1, SGLT2, β-actin or pan-cadherin. Each example shown is representative of three independent experiments. The lower panel denotes the means
±SE of three experiments for each condition determined from densitometry relative to β-actin or pan-cadherin. *Pb0.05 vs. control, **Pb0.05 vs. cAMP alone.
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membrane fraction and interaction with cav-1 and SGLTs were
blocked by cytochalasin D (Fig. 6B and C). In addition, 8-Br-cAMP-in-
duced F-actin expression in membrane fractions was attenuated by
disruption of lipid rafts with MβCD (Fig. 6D). Furthermore, 8-Br-
cAMP-induced SGLT translocation to membranes and α-MG uptake
were signiﬁcantly abolished by inhibition of cav-1 with MβCD and
siRNA (Fig. 7A and C) or by inhibition of F-actin with cytochalasin D
and TRIOBP siRNA (Fig. 7B and D).4. Discussion
This study demonstrated the regulatorymechanisms of SGLT activ-
ity by cAMP, examining the Epac and PKA signaling pathways to regu-
late: 1) the SGLT expressions via MAPKs and NF-κB and 2) the SGLT
localization to lipid rafts via cav-1 and F-actin in PTCs. To our knowl-
edge, this is the ﬁrst report suggesting that cAMP-elicited Epac and
PKAα increased glucose uptake due to increments in the number of
SGLT in an internal pool and in SGLT trafﬁcking into plasmamembrane
Fig. 6. Effect of F-actin on cav-1 and SGLTs in lipid rafts. A: PTCs were transfected with a SMARTpool of Cav-1 siRNAs (100 nmol/L) using Hyperfectamine or pretreated with cyto-
chalasin D for 30 min prior to 8-Br-cAMP treatment for 24 h. Then, cells were immunostained for SGLT2 (green) and cav-1 (red). The scale bar indicates 20 μm. B: After cells were
incubated with cytochalasin D prior to 8-Br-cAMP, cav-1 protein expression was determined with membrane fraction by Western blotting. C: After cells were treated with cyto-
chalasin D prior to 8-Br-cAMP, immunoprecipitation of anti-cav-1 was analyzed by Western blotting with antibodies that recognize cav-1, SGLT1, or SGLT2. D: After cells were in-
cubated with MβCD prior to 8-Br-cAMP, F-actin protein expression was determined with membrane fraction by Western blotting. Each example shown is representative of three
experiments. The lower panel (B, D) denotes the means±SE of three experiments for each condition determined from densitometry relative to β-actin. *Pb0.05 vs. control,
**Pb0.05 vs. cAMP alone.
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Fig. 7. Effect of inhibition of cav-1 or F-actin on SGLT translocation and α-MG uptake. A, B: PTCs were transfected with cav-1 siRNA (100 nmol/L), TRIO and F-actin binding protein
(TRIOBP) siRNA (100 nmol/L), or non-targeting control siRNA using Hyperfectamine prior to 8-Br-cAMP treatment. Protein expressions of SGLT1, SGLT2, cav-1, or F-actin were
monitored by Western blotting. Each example shown is representative of three independent experiments. The lower panels denote the means±SE of three experiments for
each condition determined from densitometry relative to β-actin. *Pb0.05 vs. control, **Pb0.05 vs. cAMP alone. C, D: After treatment with MβCD, cav-1 siRNA, cytochalasin D,
TRIOBP siRNA, or non-targeting control siRNA, α-MG uptake was measured. The values are reported as the mean ± SE of ﬁve independent experiments from triplicate dishes.
*Pb0.05 vs. control, **Pb0.05 vs. cAMP alone.
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as SGLT2 are located on detergent-resistant membranes or rafts in
apical membrane of PTCs. The importance of lipid rafts or caveolin/
caveolae within the cell membrane, which has multiple functions in
dynamic cellular processes such as signal transduction andmembrane
trafﬁcking of ion channels and transporters, has been recognized [28].
Intriguingly, previous studies provided evidence that SGLT1 is located
in detergent-resistant membrane domains or rafts, in which vimentin
forms a physical complex with caveolin [29]. In addition, optimal ac-
tivity of SGLTs is achieved when the lipid microenvironment has low
ﬂuidity [4,29,30]. Taken together, these results demonstrate that
membrane-bound cholesterol is an important modulator of glucose
transport in PTCs. Consistent with previous results, the present study
demonstrated that lipid rafts containing SGLTs could involved in reg-
ulation of cAMP-induced SGLT activity by affecting trafﬁcking and sur-
face expression. However, this is not a trivial task when considering
the complex processes of cAMP such as SGLT expression and trafﬁck-
ing. Therefore we investigated the key questions that remainregarding the junctions between the cAMP signaling network and
the SGLT expression/trafﬁcking pathway.
In the present study, we focused on roles of two cAMP effectors,
Epac and PKA. There were many studies dealing with the roles of
PKA, which stimulates the conformational change of SGLTs by phos-
phorylation [31] and the intracellular trafﬁcking of SGLTs [32]. Re-
cently, the kidney was shown to have the highest level of
expression of mRNAs encoding Epac1, expressed at the brush border
of renal PTCs [18,33]. Thus, we hypothesized that Epac, as another in-
tracellular cAMP receptor, was involved in SGLT regulation. However,
according to previous reports, Epac-dependent signaling exerts oppo-
site effects compared to PKA [34,35], and PKA-dependent signaling
stimulates apical exocytosis of Na+-K+-2Cl− cotransporters but not
Epac [36]. In the present study, 8-Br-cAMP increased Epac and PKA
activation, stimulating downstream signals such ERK, p38 MAPK,
and NF-κB, which stimulate expressions of SGLTs and cav-1. We
also previously reported that SGLT activity was regulated by MAPKs
and NF-kB signaling pathways with IL-6 in renal PTCs [37]. Consistent
981Y.J. Lee et al. / Biochimica et Biophysica Acta 1823 (2012) 971–982with present study, cAMP-induced cav-1 protein expression was
regulated by ERK, p38 MAPK, and NF-κB [38,39]. In addition, we ob-
served that cAMP analogs such as Epac activator, PKA activator, 8-
Br-cAMP, and forskolin increased SGLT1 and SGLT2 protein expres-
sion levels and α-MG uptake by SGLTs in PTCs. Based upon these
results, we propose that SGLT expression in response to cAMP is in-
creased via Epac and PKA signaling pathways. Previous reports dem-
onstrated that activity of SGLTs is regulated by the amount of
transporter within the plasma membrane, which depends on the
rate of its synthesis, its trafﬁcking, and/or its degradation [40–42].
Consequently, cAMP-induced SGLT activity depends on how newly
synthesized SGLT proteins are translocated to lipid rafts. Thus, we ex-
amined cAMP regulatory mechanisms with regards to SGLT trafﬁck-
ing between intracellular compartments and the plasma membrane.
Because the actin cytoskeleton plays an important role in
caveolae-mediated trafﬁcking and protein movement, we tested
whether F-actin is involved in cAMP-stimulated SGLT trafﬁcking
into caveolae/lipid rafts. We found that disruption of actin polymeri-
zation with cytochalasin D inhibits SGLT translocation from the cyto-
sol into cav-enriched membrane fractions. Our results suggest that
intact actin ﬁlament plays an important role in the proper positioning
of SGLTs and cAMP-stimulated trafﬁcking of SGLTs to cav-enriched
fractions in PTCs. Likewise, previous reports have shown that 8-Br-
cAMP-induced Epac and PKA modiﬁed actin cytoskeleton rearrange-
ment [43–45] and that a connection between cytoskeletal compo-
nents and caveolar-regulated cellular events. Previous reports
demonstrated that the distribution ratio of SGLT1 between intracellu-
lar and apical membranes was 2:1, and the trafﬁcking of SGLTs into
membranes was associated with the cytoskeleton [5,6,46–49]. Simi-
larly, GLUT4 translocation to the plasma membrane induced by
insulin in adipocytes is also dependent on intact actin cytoskeleton
[50]. Moreover, current trend of cellular physiology indicate that
caveolin/lipid rafts within the cell membrane provides temporal and
spatial regulation of signal transduction and membrane transporters.
More speciﬁcally, caveolin protein acts as a trafﬁcking chaperone for
lipid raft targeting of membrane proteins such as angiotensin II type
1 receptor [51], bone morphogenetic protein receptors [52], or
GLUT4 [53,54]. According to our result, caveolin-1 siRNA inhibited
8-Br-cAMP-induced translocation of SGLTs and elicited retention of
SGLTs increased by 8-Br-cAMP in cytosol, which suggest that cav-1
plays a role of trafﬁcking guidance SGLTs to lipid rafts rather than
regulating SGLT activity existed in plasma membrane. Moreover,
we observed ﬁnally that cav-1 inhibition with MβCD or siRNA and
F-actin inhibition with CyD or siRNA blocked SGLT-mediated glucose
uptake by cAMP. Taken together, cav-1 and F-actin have crucial roles
in translocation of SGLTs to lipid rafts on plasma membranes, thereby
functioning as spatial and temporal modulators of signal transduction
related to this event.
The present data sheds new light on the important mechanism by
which cAMP-induced Epac/PKA signaling pathways may give rise to
SGLT expression and translocation in PTCs. Knowledge related to
expression-trafﬁcking interactions will contribute to the understand-
ing of the mechanisms underlying the cAMP control of SGLTs in PTCs,
which holds great potential for regulating glucose homeostasis and
the discovery of novel therapeutic strategies to treat kidney diseases.
In conclusion, cAMP-induced Epac/PKA activation not only increased
SGLT expression via ERK/p38, MAPK, and NF-κB but also stimulated
SGLT trafﬁcking to plasma membranes via cav-1 and F-actin in PTCs.Acknowledgements
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